Mark your calendar for Wednesday 23rd & 30th April at 3pm BST | 4pm CEST | 10am ET.
Discover how cutting-edge proteomics is reshaping drug discovery.
Proteins are the target of over 9-% of approved drugs, but many critical disease-associated proteins remain “undruggable”. Advances in proteomics – ranging from covalent screening and mass spectrometry to AI-driven insights – are transforming our ability to understand, target and modulate the proteome in powerful new ways.
In this two-part webinar series, researchers will share case studies and emerging strategies that are unlocking novel therapeutic opportunities.
By attending this webinar series, you will learn:
- How chemoproteomics, thermal profiling, and AI are expanding our understanding of the proteome and potential therapeutic targets.
- Strategies to target the proteome with novel mechanisms of action.
- How to move from proteomic data to actionable therapeutics.
**Please note that by registering for the first webinar in the series you will automatically gain access to the second webinar.**
Webinar 1: Unlocking The Power of Proteomics for Drug Discovery
Wednesday 23 April, at 3pm BST | 4pm CEST | 10am ET
This webinar will explore how cutting-edge proteomics technologies are shaping the future of drug development. Topics include mass spectrometry, covalent chemoproteomics, and thermal proteomic profiling.
Talk 1: Expanding The Druggable Proteome Through Covalent Chemoproteomics
- Jacob Bush, Director, Chemical Biology, GSK
Talk 2: Thermal Proteomic Profiling for Drug Discovery Applications
- Andre Mateus, Assistant Professor, Umeå Universitet
Talk 3: Investigating the Cell-Membrane Proteome of Cancer and Brain TME Cells for Advancing the Drug Target Discovery Process
- Iulia Lazar, Professor, Biological Sciences, Virginia Tech
Webinar 2: Proteomics Driving New Therapeutic Approaches
Wednesday 30 April, at 3pm BST | 4pm CEST | 10am ET
This webinar will focus on how advances in proteomics are accelerating drug target identification, supporting the design of drugs, giving rise to new modalities, and providing key insights into whether these drugs will be effective.
Talk 1: POLYPHARM-AI: Harnessing Molecular Drivers of Comorbidity for Precision Drug Discovery
- Jeffrey Skolnick, Regents’ Professor, Georgia Institute of Technology
Talk 2: Chemical Proteomics to Develop Drugs with Novel Mechanisms of Action
- Madeline Kavanagh, Assistant Professor of Chemical Biology, Leiden University
Talk 3: Developing Pan-Kras Targeted Protein Degraders
- Ilaria Puoti, Cellular and Proteomic Scientist, University of Dundee
